Introduction {#S1}
============

Chronic health problems in cancer survivors include cardiovascular diseases (CVDs), which are the primary causes of morbidity and mortality in this population. There is a significant correlation between increased risk of CVDs and chest irradiation, which results in short-term and long-term cardiovascular complications in cancer survivors ([@B2]). Although acute pericarditis can result from high dose radiation, radiation-induced heart injury may take decades to become symptomatic ([@B138]). Common CVDs include accelerated atherosclerosis, myocardial remodeling, fibrosis, and injury to cardiac valves. Recent epidemiological, clinical, and preclinical studies have shown strong evidence that ionizing radiation can cause cardiovascular injury ([@B169]; [@B219]; [@B193]). The underlying mechanisms of radiation-induced cardiovascular injury have not been characterized due to the wide spectrum of complex effects of ionizing radiation on the cardiovascular system.

Recent studies showed that NLRP3 inflammasome upregulation and activation were associated with radiation damage ([@B203]). However, the role of the NLRP3 inflammasome in radiation-induced damage requires further characterization. In this review, we focused on relevant epidemiological and clinical evidence for radiation-induced CVDs. We also reviewed the role of the NLRP3 inflammasome in radiation-induced injury, and highlighted possible therapeutic strategies for preventing radiation-induced heart disease (RIHD).

Overview of Radiation-Induced Cardiovascular Diseases {#S2}
=====================================================

Clinical Evidence for Radiation-Induced Cardiovascular Diseases {#S2.SS1}
---------------------------------------------------------------

Survivors of childhood cancer and Hodgkin's lymphoma who experienced conventional fractionated radiotherapy (total tumor dose of 30--40 Gy) are at greater risk of late cardiac death than the general population ([@B169]). Long-term follow-up of over 1,400 patients with Hodgkin's lymphoma with a history of radiotherapy showed a significant increase in standardized incidence ratio of myocardial infarction (MI), angina, valve disease, and congestive heart failure. In addition, patients who received radiotherapy at a young age (\<20 years-old) are at significantly higher risk for MI (5.4 standard incidence ratio) than patients irradiated at age 36--40 (2.6 standard incidence ratio). Anthracycline chemotherapy further increased the risk of cardiovascular events in young patients with a history of thoracic irradiation ([@B4]). Head and neck cancer patients with a radical radiotherapy history often experience a significant dose of radiation to the carotid arteries. Subsequent vascular injury may result in atherosclerosis, and increased risk of stroke and transient ischemic attack (TIA) ([@B157]).

[@B135] and [@B185] showed a relationship between cardiovascular death and cardiac radiation dose in childhood cancer survivors. These studies showed that the relative risk of cardiovascular death caused by radiotherapy was significantly associated with mean heart dose, particularly when cardiac doses were ≥ 15 Gy. Mean heart doses over 35 Gy were linked with even greater hazard ratios. Prospective studies showed that the majority of survivors of Hodgkin's lymphoma exhibited asymptomatic cardiovascular abnormalities (e.g., conduction defects, valve dysfunction, and diastolic dysfunction). These findings suggested that occult RIHD may be underestimated in this patient population. Whether low-dose irradiation damages the cardiovascular system is unknown.

Mean heart doses and dose distribution to certain cardiac structures were estimated in patients with breast cancer who underwent post-operative irradiation (50 Gy in 25 fractions) up to the early 1990s ([@B180]). Left-side breast cancer patients, of whom some received internal mammary chain radiation, experienced total average doses of 3--17 Gy across the entire heart. A large-scale investigation suggested that exposure of the internal mammary chain to radiation correlated with a significantly increased risk of cardiovascular abnormalities (average cardiac dose was 6--15 Gy). Patients who underwent breast irradiation alone with a mean heart dose \< 7 Gy were not at increased risk for development of CVD ([@B82]). However, the effect of low dose irradiation (\<2.5 Gy) on the cardiovascular system is unknown. A life-span investigation of Japanese atomic bomb survivors indicated that cardiac abnormalities such as inflammation and fibrosis were increased by exposure to low dose radiation ([@B164]).

Experimental Evidence for Radiation-Induced Cardiovascular Diseases {#S2.SS2}
-------------------------------------------------------------------

Use of experimental animals to estimate RIHD is convenient due to shorter life spans and ease of follow-up. Radiation-induced cardiovascular injury depends on timing, dose and fraction, and extent of radiation exposure to the heart and blood vessels. However, most animal studies have applied single high doses or a total high dose across a limited number of fractions ([@B175]). Local single high doses of radiation are more frequently applied to young adult (male) animals. Rodent models are widely used to identify potential biological mechanisms of radiation-induced cardiac injury. Larger animals, such as rats, rabbits, and cynomolgus monkeys, have been used for decades to study RIHD ([@B13]).

Although myocardial changes have been shown to be similar in animals and humans, radiation-induced accelerated atherosclerosis has not been frequently observed in common animal models ([@B14]). Several research groups have reported that increased perivascular and interstitial collagen deposition in the myocardium was observed several months after local cardiac radiation in mice ([@B156]; [@B186]). Increased collagen deposition was accompanied by local increased fibrotic cytokine expression. [@B15] found that induction of TGF-β expression further enhanced radiation-induced cardiac fibrosis. Moreover, this radiation-induced fibrosis worsened with loss of microvasculature density and function in the myocardium ([@B179]).

To investigate radiation-induced accelerated atherosclerosis, inclusion of additional cardiovascular risk factors in experimental models is necessary. Genetically modified mouse models susceptible to atherogenesis, such as LDL receptor-deficient mice (*Ldlr*^--/--^) and apolipoprotein E-deficient mice (*Apoe*^--/--^), are commonly used ([@B154]; [@B168]). High dose radiation to the neck of *Apoe*^--/--^ mice led to increased atherosclerotic plaque formation and increased macrophage abundance in the carotid artery ([@B83]). In addition, local heart radiation resulted in microvascular injury and atherosclerosis in the coronary arteries of *Apoe*^--/--^ mice that was more extensive ([@B48]). Pathophysiological changes in the cardiovascular systems of small animals exposed to radiation are similar to those in clinical specimens, including increased intima-media thickness and more artery wall lesions ([@B187]).

Pathological Features of Radiation-Induced Cardiovascular Diseases {#S2.SS3}
------------------------------------------------------------------

Atherosclerosis and fibrosis are typical pathological changes in RIHD, but the pathophysiology of these changes is poorly understood ([@B214]). Many of the pathological changes in vascular structure secondary to radiation may be much the same as those observed in typical atherosclerosis. However, radiation-accelerated coronary atherosclerosis results in more extensive media damage and adventitia fibrosis compared with ordinary coronary atherosclerosis. In addition, more lipid and calcium deposition has been shown to occur in radiation-induced fibrous tissue of intimal plaques than in non-irradiated atherosclerotic plaques ([@B192]). [@B19] found that more than one-fourth of the major coronary arteries were nearly completely narrowed when cross-sections were evaluated. The proximal half of the right and left anterior descending coronary arteries are frequently damaged by radiation ([@B19]). Moreover, intramyocardial coronary thickening and myocardial fibrosis of the right ventricle have been observed in response to radiation. The endocardium was significantly thickened in the right ventricle of many patients who underwent radiation ([@B177]). Similarly, valve thickening, particularly of the tricuspid valve, occurred in over 80% of patients who underwent irradiation ([@B62]). Nearly all patients experienced pericardial and epicardial fibrosis following radiotherapy, and pericardial tamponade was also common.

Cervical radiotherapy-induced carotid lesions exhibit a greater degree of stenosis than non-typical atherosclerotic lesions. Radiation-induced carotid lesions are frequently observed in the external and common carotid artery. Similar to radiation-accelerated coronary atherosclerosis, ionizing irradiation-induced carotid stenosis presents a more stable phenotype than *de novo* atherosclerotic plaques ([@B44]). Macrophage infiltration was observed less frequently in response to radiation, but more fibrous plaques were present following cervical irradiation-induced carotid lesions ([@B63]).

Radiation and NLRP3 Inflammasome Activation {#S3}
===========================================

Overview of the NLRP3 Inflammasome {#S3.SS1}
----------------------------------

A sensor protein (NLRP3), an adaptor protein (apoptosis-associated speck-like protein containing a caspase recruitment domain, ASC), and an effector protein (cysteinyl aspartate specific protease 1, caspase-1) comprise the NLRP3 inflam- masome. Nucleotide-binding domain and leucine-rich-repeat-containing family pyrin 3 is comprised of three domains: an amino-terminal pyrin domain (PYD), a central NATCH domain (an evolutionarily conserved protein domain contains NLP family apoptosis inhibitor protein, MHC class II transcription activator, incompatibility locus protein from *Podospora anserina*, and telomerase-associated protein), and a carboxy-terminal leucine-rich repeat (LRR) domain ([@B155]). The NATCH domain possesses ATPase activity responsible for NLRP3 self-assembly and function. The LRR domain is responsible for self-inhibition through the NATCH domain. Apoptosis-associated speck-like protein containing CARD (ASC) functions as an adaptor protein with two protein-interacting domains. The amino-terminal domain of the ASC is PYD, and the carboxy-terminal domain is the caspase recruitment domain (CARD) that interacts with inflammatory caspase-1. Upon stimulation, oligomerization of NLRP3 occurs via NATCH--NATCH domain interactions, following by the recruitment of ASC and caspase-1 via homotypic interactions with CARD. Activated caspase-1 then cleaves the pro-inflammatory cytokines IL-1β and IL-18 to their bioactive forms ([@B174]). In addition, inflammasome activation results in pyroptosis, a form of cell death characterized by loss of cell integrity, cellular swelling, and lysis ([@B218]). Pyroptosis correlates with active IL-1β and IL-18 release by three different mechanisms: secretion through pores formed by active gasdermin D (GSDMD) on the membrane, shedding of microvesicles, and lysosome-mediated exocytosis ([@B158]). Endogenous danger-associated molecular patterns (DAMPs), such as high mobility group box 1 (HMGB1), APT, and IL-1α produced by stressed cells further activate the NLRP3 inflammasome. Activation of these signaling pathways results in an enhanced inflammatory response ([@B9]).

In addition to the role of canonical NLRP3 function in activation of caspase-1, non-canonical activation of NLRP3 activated caspase-4/5 in humans and caspase-11 in mice in a TLR-independent manner ([@B191]; [@B216]). A recent study suggested that NIMA-related kinase 7 (NEK7) might be critical to activation of the NLRP3 inflammasome. Upon inflammasome activation, NEK7 was shown to oligomerize with NLRP3 to form a complex, which indicated that NEK7 was a component of the NLRP3 inflammasome ([@B76]).

Radiation Triggers NLRP3 Inflammasome Activation {#S3.SS2}
------------------------------------------------

Inflammasome activation is considered a two-step "priming and activation" process. Priming is characterized by upregulation of the expression of inflammasome core components and induction of post-translational modifications (PTMs) such as ubiquitylation, SUMOylation, and phosphorylation ([@B174]). In addition, interfering RNAs modulate the expression of NLRP3 at the transcriptional level ([@B182]). The second step initiates inflammasome formation upon activation. Nucleotide-binding domain and leucine-rich-repeat-containing family pyrin 3 is an effector of the innate immune response that recognizes pathogen-associated molecular patterns (PAMPs) or DAMPs by engaging pattern recognition receptors (PRRs) ([@B93]). In addition, NLRP3 can be activated by a number of other stimuli. Furthermore, non-infectious stimuli such as endogenous DAMPs and exposure to environmental irritants can activate the NLRP3 inflammasome. Most activators of NLRP3 are produced by cellular stress responses ([@B9]). The mechanisms by which NLRP3 senses cellular stress and the signaling pathways involved in NLRP3 activation and inflammasome formation are poorly understood. Activation of NLRP3 may involve multiple upstream pathways, but there is no consensus model. Upstream signals of NLRP3 activation are often interrelated and overlapping, including ion internalization and efflux, lysosomal disruption, mitochondrial disorders, metabolic dysfunction, and sphingolipid metabolic changes ([@B107]).

Radiation can activate NLRP3 inflammasome via multiple mechanisms. Radiation-related potassium ion efflux and calcium flux have been studied extensively ([@B129]; [@B101]; [@B45], [@B46]; [@B183]). Calcium influx into the cytosol can occur through opening of plasma membrane channel or release from the endoplasmic reticulum (ER) intracellular Ca^2+^ pool. Potassium efflux functions as a counter regulator of Ca^2+^ influx. As such, Ca^2+^ influx and K^+^ efflux are often found to be coordinated in NLRP3 activation ([@B215]). Adenosine triphosphate is another key signaling molecule that mediates radiation-induced biological effects ([@B96]). Stimulation of the P2X purinoceptor 7 (P2X~7~) by ATP induces weak Ca^2+^ and Na^+^ influx, with concurrent K^+^ efflux ([@B59]; [@B91]). Low intracellular K^+^ has been shown to activate the NLRP3 inflammasome in THP1 cells and bone-marrow-derived macrophages *in vitro* ([@B144]). Radiation can also directly induce cholesterol biosynthesis ([@B205]). Longitudinal trends in total serum cholesterol levels of atomic bomb survivors also supported the ability of radiation to induce cholesterol biosynthesis ([@B207]). Phagocytosis of cholesterol crystals results in lysosomal rupture and release of particles into the cytoplasm. Radiation can directly induce lysosomal destabilization ([@B143]). Cholesterol crystals and radiation have been shown to induce lysosomal rupture, resulting in NLRP3 activation ([@B36]). In addition, cathepsins released from ruptured lysosomes have been shown to play a critical role in NLRP3 activation following radiation treatment ([@B6]). However, individual knockouts of cathepsin B, X, L, or S had little effect on NLRP3 activation, which demonstrated that cathepsins may have redundant roles in activation of NLRP3 signaling ([@B139]). Recent studies have suggested that radiation-induced up-regulation of cellular ceramide ([@B99]; [@B161]) acts as a second messenger in initiation of intrinsic apoptosis. Ceramide plays multiple pathophysiological roles during radiation-induced NLRP3 activation. Ceramide-induced cathepsin D activation has been shown to link TNFα-induced acid sphingomyelinase to Bid-related mitochondrial apoptosis ([@B77]). Recent studies identified plasma membrane ion channels as novel targets of ceramide, such as those responsible for Ca^2+^ influx and K^+^ efflux ([@B176]; [@B108]; [@B29]). These findings show that many mechanisms of NLRP3 activation involve either Ca^2+^ or K^+^ flux.

Most radiation damage results from water radiolysis, as 80% or more of total cell mass or tissue is comprised of water. Ionizing irradiation-induced water radiolysis generates reactive oxygen species (ROS), the main source of radiation-induced tissue damage. NLPR3 protein contains a highly conserved disulfide bond connecting the PYD domain and the nucleotide-binding site domain that is highly sensitive to altered redox state ([@B8]). Radiation-induced mitochondrial dysfunction, and release of mitochondrial ROS and DNA into the cytoplasm, are essential upstream regulators of NLRP3 activation ([@B24]). Ionizing radiation can also effectively generate ozone, which has been suggested to have a strong association with cardiovascular injury ([@B167]; [@B196]). Ozone induced oxidative stress causes inflammasome activation with the release of IL-1 and inflammatory cytokines ([@B132]). ROS may serve as both "kindling" and "bonfire" for NLRP3 inflammasome activation. ROS can function as a redox signaling messenger to trigger NLRP3 inflammasome activation ([@B1]). When NLRP3 inflammasome is activated, "bonfire" $\text{O}_{2}^{\bullet -}$ and inflammatory cytokines are generated. Excess ROS results in intracellular and extracellular oxidative stress, and damage of nucleotides, lipids, proteins eventually and inevitably. Although there is a plethora of evidence supporting radiation-induced ROS activation of NLRP3 inflammasomes, the exact mechanisms are still largely unknown. Two distinct proteins, thioredoxin-interacting protein (TXNIP) and mitochondrial antiviral signaling protein (MAVS), are demonstrated as possible mediators of ROS to activate NLRP3 inflammasomes ([@B233]; [@B171]). Moreover, irradiation damage induces mitosis and pyroptosis, resulting in generation of DAMPs and activation of the NLRP3 inflammasome. Reports have shown persistent expression of NF-κB, which promotes NLRP3 transcription, in patient neck vessels over 10 years post-radiation ([@B68]). This finding further indicated a possible link between NF-κB-dependent NLRP3 activation and chronic fibrosis.

The Role of the NLRP3 Inflammasome in Radiation-Induced Cardiovascular Diseases {#S4}
===============================================================================

Recent studies have indicated that upregulation of the NLRP3 inflammasome may play an essential role in RIHD ([@B203]). NLRP3 inflammasome has been shown as the primary generator responsible for IL-1 production in atherosclerosis and other CVDs ([@B61]). Significant increase in secretion of inflammatory cytokines IL-1β and IL-18 was reported in irradiated-animal models ([@B81]; [@B67]). IL-1 was suggested to participate in the development of radiation-induced cardiomyopathy ([@B131]). Gene expression of IL-1β was significantly elevated during the first month in rat heart after local ionizing irradiation ([@B104]). A markedly increased IL-1 expression was observed in irradiated human arteries and veins when compared to non-irradiated ([@B27]). Increased level of pro-caspase-1 and caspase 1 in human arteries with chronic radiation injury indicated the involvement of NLRP3 inflammasome in RIHD ([@B28]). However, the outcomes of vascular damage at organ subsites have not been fully characterized, for example, the underlying mechanisms of NLRP3 in radiation-induced CVDs have not yet been established. In this section, we summarized current knowledge of the consequences and molecular mechanisms of RIHD, with a particular focus on the NLRP3 inflammasome in RIHD.

NLRP3 Inflammasome in Radiation-Induced Atherosclerosis {#S4.SS1}
-------------------------------------------------------

Activation of the NLRP3 inflammasome has been extensively investigated in macrophages and atheroma cells, including smooth muscle cells (SMC), endothelial cells (ECs), and T cells, each of which play significant roles in onset and development of atherosclerosis ([@B50]). Recent studies suggested that NLRP3 may have additional functions beyond a regulatory role in inflammasome signaling and the innate immune response ([@B78]). These findings indicated that NLRP3 may be involved in radiation-induced atherosclerosis.

Many endogenous danger signals are present in radiation-induced atherosclerosis, which indicates that the NLRP3 inflammasome may be linked to metabolic disturbances, irradiation damage, and inflammation. Limited studies have evaluated the role of the NLRP3 inflammasome in the pathogenesis of irradiation-induced atherosclerosis, but the role of the NLRP3 inflammasome has been extensively studied in non-irradiation-induced atherosclerosis.

Several epidemiological studies have shown a correlation between aortic NLRP3 expression and CVD ([@B61]). Components of the NLRP3 inflammasome are expressed in atheromatous cells ([@B9]). High aortic expression of NLRP3 has been observed in patients with coronary atherosclerosis. The expression of NLRP3 was correlated with the severity of narrowing or blockage of the coronary artery ([@B195]). Moreover, aortic NLRP3 expression has been shown to be directly associated with CVD severity and multiple clinical risk factors ([@B229]). Analysis of human carotid atherosclerotic plaques showed significantly elevated expression of NLRP3, ASC, caspase-1, IL-1β, and IL-18 compared to those in control mesenteric or iliac arteries ([@B162]). Furthermore, symptomatic patients with CVD have markedly higher NLRP3 expression than asymptomatic patients. Active atherosclerotic plaques exhibit higher expression of NLRP3 inflammasome components than stable atherosclerotic plaques ([@B142]). In addition, patients with acute coronary syndrome showed significantly increased NLRP3 expression in peripheral blood monocytes, which was directly associated with the severity of the disease ([@B234]).

Two murine models developed on the C57BL/6 background, *Apoe*^--/--^ and *Ldlr*^--/--^, have been widely used to investigate the mechanisms of atherogenesis ([@B40]). However, these models leverage distinctly different mechanisms to induce diet-induced atherosclerosis ([@B54]). The importance of activation of the NLRP3 inflammasome in irradiation-induced atherogenesis was first detailed by [@B36], who found that bone marrow transplanted from *Nlpr3*^--/--^, *Asc*^--/--^, or *Il1*α^--/--^/*Il1*β^--/--^ mice into irradiated-*Ldlr*^--/--^ mice resulted in impaired progression of atherogenesis. [@B79] recently showed that activation of caspase-1 and caspase-11 were important in diet-induced atherosclerosis using irradiated *Ldlr*^--/--^ mice transplanted with bone marrow from caspase-1 or caspase-11 deficient mice.

Ionizing radiation can also accelerate the development of atherosclerotic lesions in *Apoe*^--/--^ mice ([@B168]). Depletion of inflammasome components has been shown to suppress atherogenesis in *Apoe*^--/--^ mice. [@B230] showed that NLRP3 inflammasome activation was involved in atherogenesis by silencing *NLRP3* in *Apoe*^--/--^ mice, which resulted in decreased atherogenesis. Two other groups showed reduced atherogenic plaque progression in *caspase-1*^--/--^/*Apoe*^--/--^ dual knockout mice fed a low cholesterol diet ([@B49]; [@B188]). In addition, spontaneous development of atherosclerosis was reduced in chow-fed *caspase-1*^--/--^/*Apoe*^--/--^ mice. Inhibition of IL-18 activity or IL-18 deletion in *Apoe*^--/--^ mice markedly attenuated atherosclerotic plaque progression compared to control mice ([@B122]). In addition, *IL-1*β^--/--^/*Apoe*^--/--^ knockout mice showed a 30% reduction in plaque development compared to *Apoe*^--/--^ control mice ([@B94]). Another study showed a prominent reduction in plaque size in both *Il1*β^--/--^/*Apoe*^--/--^ and *Il1*α^--/--^/*Apoe*^--/--^ double knockout mice compared to that in *Apoe*^--/--^ control mice. Similar findings were observed in radiation-treated *Apoe*^--/--^ mice transplanted with bone marrow from *Il1*α^--/--^ or *Il1*β^--/--^ mice ([@B90]). However, *Nlpr3*^--/--^/*Apoe*^--/--^, *Asc*^--/--^/*Apoe*^--/--^, and *caspase-1*^--/--^/*Apoe*^--/--^ mice did not exhibit decreased progression of atherosclerosis, which indicated that atherosclerosis can proceed independently of NLRP3 inflammasome activation ([@B128]). Although *Apoe*^--/--^ mice exhibit more rapid and more severe progression of diet-induced atherosclerosis than *Ldlr*^--/--^ mice, spontaneous atherosclerosis, even when fed a normal chow diet, is frequently observed in *Apoe*^--/--^ mice ([@B54]). The suitability of the *Apoe*^--/--^ mouse model for study of atherogenesis remains controversial. A possible explanation is that compensatory inflammatory signaling may drive progression of atherogenesis at later stages of the disease ([@B61]). This hypothesis was supported by findings that both IL-1β and IL-1α signaling are required for atherogenesis ([@B47]). IL-1α immediately presents its bioactive form after transcription in a NLRP3 inflammasome-independent manner ([@B71]). Prolonged atherogenic stimulation in *Ldlr*^--/--^ mice transplanted with bone marrow of *Il1*α^--/--^ mice resulted in less significant atherosclerotic lesions than those observed in mice transplanted with bone marrow from *Il1*β^--/--^ mice ([@B47]). These findings highlighted the involvement of IL-1α, but not IL-1β, in atherogenic progression following prolonged administration of an atherogenic diet.

Though the long-term adverse effects of radiation on organs, and the involvement of activation of the NLRP3 inflammasome in radiation-induced injury, have been extensively demonstrated ([@B203]), the underlying mechanisms responsible for RIHD are poorly understood. Whether the NLRP3 inflammasome plays a role in onset or development of radiation-accelerated atherogenesis, or both, has not been determined.

Multiple atherogenic factors, which can be induced by ionizing radiation, have been shown to activate the NLRP3 inflammasome, followed by endothelial damage and subsequent atherogenesis. Activation of the NLPR3 inflammasome has been reported to directly induce endothelial dysfunction ([@B226]; [@B41]; [@B98]). A recent study showed that inhibition of radiation-induced NLRP3 inflammasome activation by LGM2605, an antioxidant and free radical scavenger, alleviated vascular damage ([@B22]). Inhibitors of HMGB1 or caspase-1 significantly ameliorated endothelium-associated vasodilation in poloxamer 407 (P-407)-treated *Nlrp3*^+/+^ mice ([@B226]). In addition, activation of endothelial NLRP3 inflammasome was partially correlated with lysosomal disruption in coronary arteritis, which resulted in endothelial dysfunction ([@B23]). Induction of cold-inducible RNA-binding protein by irradiation causes endothelial dysfunction via activating NLRP3 inflammasome ([@B213]). Heme, released from damaged RBCs (possibly by radiation under certain conditions), can function as a DAMP to induce IL-1β secretion through NLRP3 activation ([@B41]). Heme-induced elevation of IL-1β levels was intensified by LPS priming ([@B41]). Acute hypercholesterolemia has been shown to significantly impair endothelium-associated vasodilation in wide-type mice. However, this effect was markedly attenuated in *Nlrp3*^--/--^ mice ([@B226]). Li and colleagues recently found that acid sphingomyelinase (ASMase, encoded by gene *Smpd1*) and ceramide-associated membrane raft (MR) signaling platforms were involved in endothelial NLRP3 inflammasome activation and atherogenesis resulting from hypercholesterolemia ([@B97]). Cholesterol crystal administration significantly promoted NLRP3 inflammasome formation and activation in murine carotid arterial endothelial cells, as evidenced by augmented colocalization of NLRP3 with other inflammasome components and enhanced caspase-1 activity and IL-1β production. These effects were significantly reduced by silencing or deletion of mouse *Smpd1* or treatment with an ASM inhibitor. Neointimal formation that is more severe, significant intimal inflammasome formation, and increased IL-1β expression were associated with elevated NLRP3 in *Smpd1*^+/+^ mice compared with those in *Smpd1*-deficient mice. These data showed that ASMase and ceramide-related MR clustering are critical for activation of inflammasomes and subsequent endothelial dysfunction in the carotid arteries, resulting in progression of atherosclerosis ([@B97]).

Radiation can directly damage cardiovascular endothelial cells through multiple mechanisms, which can further enhance the pathophysiological effects of the NLRP3 inflammasome. Single and fractionated ionizing radiation significantly affect vasculature by altering endothelial expression of connexins and increase release of ATP ([@B147]). Conventional fractionated ionizing radiation induces mitotic catastrophe (mitotic cell death distinct from apoptosis) in ECs ([@B51]). Radiation (≥10 Gy) can induce cell cycle arrest and Bax-mediated apoptosis of endothelial progenitor cells (EPCs), and cause cellular senescence in well-differentiated ECs similar to that observed in premature atherosclerosis ([@B190]). Radiation-induced cell death, which is characterized by mitotic catastrophe, apoptosis, and senescence, could stimulate an acute reduction in capillary density or induce chronic inflammation, resulting in disruption of vascular homeostasis ([@B190]).

Radiation-related DNA damage-induced EC senescence often results in secretion of cytokines, proteins, and extracellular vesicles ([@B5]). The senescence-related secretory phenotype of ECs results in dysfunction of adjacent cells or chronic inflammation. A study showed that irradiation increased the expression of the aging-related atherosclerotic senescence marker CD44 ([@B136]) in human coronary ECs and increased monocyte adhesion to ECs ([@B121]). Radiation can also activate NEMO-dependent NF-κB signaling, which is involved in transcription and upregulation of NLRP3 ([@B198]), cytokines ([@B126]), and adhesion molecules ([@B113]). Furthermore, irradiation also activates TNFα, resulting in ceramide generation via hydrolysis of sphingomyelin. Ceramides can induce the expression or activation of NF-κB, an important proinflammatory transcription factor ([@B95]; [@B56]), Moreover, ceramides can directly trigger NLRP3 inflammasome activation ([@B189]; [@B100]; [@B153]). In addition, radiation disrupts inflammatory homeostasis in the vascular microenvironment by increasing the expression of selectins, integrins, and adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) ([@B70]; [@B145]). However, the effect of radiation on initiation of NF-κB/NLRP3 signaling, upregulation of adhesion molecules, and recruitment of monocytes/macrophages depends on the types and fractions of radiation, and the types of endothelial cell exposed to radiation ([@B125]). Irradiation-induced EC dysfunction may occur in NLRP3 inflammasome-dependent and -independent manners.

Vascular smooth muscle cells (VSMCs), which are major components of medium and large arteries, participate in arterial wall remodeling and atherogenesis throughout all stages of atherosclerosis ([@B84]). Although mechanisms of atherogenesis remain poorly understood, studies have shown that crosstalk between inflammatory cells and ECs and VSMCs contributes to CVD progression. Some of these interactions accelerate the genesis and stability of atherosclerotic plaques ([@B109]). Tracing of SMC lineage in *Apoe*^--/--^ mice fed a long-term western-diet has contributed to understanding of the role of VSMC in atherosclerosis ([@B160]). Vascular smooth muscle cells in atherosclerotic lesions have been shown to be derived from a subset of medial Myh11^+^ VSMCs that propagate the lesions ([@B21]). Most VSMCs within atherosclerotic sites lack characteristic SMC marker expression profiles, but they express markers of mesenchymal stem cells, myofibroblast-like cells, or macrophages ([@B11]). [@B133] demonstrated the role of proliferation, migration, and fibrogenic phenotype transition of VSMCs in irradiation-induced vascular damage. Co-culture of VSMCs with irradiated ECs resulted in significantly increased proliferation and migration. Further study showed that TGF-β/Smad3 signaling played a role in irradiated EC-induced fibroblastic phenotype transition of VSMCs. However, the role of the NLPR3 inflammasome in VSMC-mediated atherosclerosis has not been characterized. Wang and colleagues found that NLRP3 inflammasome activation promoted foam cell formation in human VSMCs and induced atherogenesis in *Apoe*^--/--^ mice via release of HMGB1 ([@B197]). Moreover, NLRP3 inflammasome activation has been shown to induce VSMC synthetic phenotype transition and proliferation ([@B172]). Deficiency of NLRP3 has been shown to reduce Ang II-induced NLRP3 inflammasome activation, synthetic phenotypic transition, and proliferation in murine VSMCs ([@B148]). However, [@B36] found that lethal irradiation (12 Gy) of *Apoe*^--/--^ mice resulted in loss of VSMC accumulation in the brachiocephalic and carotid artery, but VSMC levels in the aortic root and in abdominal aortic lesions were normal ([@B137]). These studies demonstrated differences in the sensitivity to radiation of VSMCs in different vascular beds.

Priming and activation signals are required for NLRP3 inflammasome activation in macrophages. This two-step mechanism tightly regulates activation of NLRP3 inflammasome in macrophages. Nucleotide-binding domain and leucine-rich-repeat-containing family pyrin 3 is easily activated by a variety of DAMPs generated by ionizing radiation. Radiation can induce inflammatory cytokine production in macrophages ([@B181]) and can trigger NLRP3 inflammasome activation, resulting in macrophages pyroptosis ([@B119]). Pyroptosis is a rapid and highly inflammatory form of programmed cell death that can be initiated by DAMP-activated NLRP3 inflammasome ([@B65]). Moreover, NLRP3 inflammasome activation has been shown to augment lipid-deposition and macrophage migration ([@B111]). Macrophage recruitment is the primary response to radiation-induced damage ([@B3]), and macrophage polarization is affected during the early and late stages of radiation-induced tissue damage ([@B37]; [@B130]). Radiation promotes pro-inflammatory M1 macrophage polarization, which results in enhanced production of M1 cytokines such as TNF-α, interleukins, and IFN-γ ([@B43]). Mature M1 macrophages accelerate extracellular matrix breakdown, tissue damage, and fibrosis ([@B17]). In fact, ionizing radiation can activate NLRP3 inflammasome in multiple immune cells, including T and B lymphocytes ([@B170]). Both myeloid and adaptive response are involved in atherogenesis ([@B206]).

NLRP3 Inflammasome Regulation of Radiation-Induced Cardiovascular Fibrosis {#S4.SS2}
--------------------------------------------------------------------------

The endpoint of RIHD is cardiovascular fibrosis, which is a severe complication associated with a high rate of mortality. Radiation-induced fibrotic diseases of the cardiovascular system include radiation-related coronary artery disease with manifest fibrous tissue, myocardial fibrosis, cardiomyopathy, valvular fibrosis, and fibrosis of the pericardium. Vascular endothelial damage is widely considered to be the primary pathogenic signal that precedes fibrosis ([@B214]).

Radiation damage induces early and delayed cardiac tissue injury. Ionizing radiation induces early endothelial damage, which results in vasodilation and increased blood vessel permeability ([@B165]). Injured ECs secrete inflammatory cytokines (TNFα, IL-1, IL-6, and IL-8), resulting in upregulation of adhesion molecules and activation of the inflammatory response. Inflammatory cells recruited to lesions produce profibrotic cytokines including transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), and connective tissue growth factor ([@B32]). Radiation-induced cardiovascular injury triggers a complex cascade of cellular and molecular responses that result in tissue fibrosis. Fibrogenesis consists of four major phases: (1) The initiation stage is driven by primary vascular endothelial injury. The central event during this phase is recruitment of inflammatory cells, which produce a number of mediators, cytokines, and other factors that strengthen the inflammatory response; (2) Activation of fibrogenic effector cells, include fibroblasts, fibrocytes, tissue-specific pericytes, and myofibroblasts. These types of cells can proliferate and differentiation into mature myofibroblasts in response to injury; (3) Elaboration of the extracellular matrix occurs when effector cells produce a large amount of extracellular matrix proteins, primarily in an autocrine manner. In addition, cell--cell interactions lead to further activation of effector cells, resulting in a positive feedback loop. This process is driven by TGF-β and PDGF; (4) The final stage is fibrosis, which results in organ dysfunction and failure ([@B150]).

Myocardial fibrosis commonly features reactive fibrosis and replacement fibrosis ([@B184]). Reactive fibrosis often occurs in the perivascular space, and replacement fibrosis occurs at locations where myocytes are lost. Radiation-induced myocardial fibrosis may be induced by cardiac fibroblasts, which are the most abundant non-myocyte cell type in the myocardium ([@B103]). A recent study indicated that NLRP3 inflammasome in fibroblast linked inflammation with tissue injury ([@B42]). Cardiac fibroblasts might originate from myocardial mesenchymal cells, bone marrow-derived circulating fibroblasts, and epithelial/endothelial--mesenchymal cell transition (EndoMT/EMT) ([@B134]). EndoMT is a transition process where ECs lose their endothelial characteristic features and obtain mesenchymal properties. Mounting evidence indicated that EndoMT contributed to cardiac fibrosis ([@B102]). Nearly one-third of all cardiac fibroblasts originated from ECs ([@B221]). A recent study showed that NLRP3 inflammasome activation during the EMT linked inflammatory injury and endothelial dysfunction ([@B26]). In addition, studies have shown that myofibroblasts can also originate from resident VSMCs during atherogenesis, as evidenced by expression of smooth muscle myosin heavy chain (SMMHC) and alpha-smooth actin (αSMA). Skin biopsy samples from patients who underwent breast radiotherapy showed collagen accumulation and fibroblast expression of αSMA, which indicated a myofibroblast phenotype. Benderitter and colleagues reported prominent ECM deregulation and VSMC proliferation in hypertrophic blood vessels in patients who received preoperational radiotherapy, as evidenced by the presence of αSMA-expressing cells in the condensed collagen matrix region of intimal hyperplasia. *In vitro* co-culture experiments showed that VSMCs co-cultured with irradiated human endothelial cells underwent myofibroblastic transition ([@B133]). Zhang and colleagues recently reported that PDGF-BB stimulation of *Spmd1*-deficient VSMCs induced differentiation to a myofibroblast-like phenotype, as evidenced by marked upregulation of fibroblast-specific protein (FSP-1) expression, massive collagen type I deposition, increased IL-6 release, and upregulation of adhesion molecule expression ([@B223]). The underlying mechanism of these effects may be due to prolonged Akt activation, and p62/SQSTM1-dependent NRF2 upregulation and nuclear translocation. These findings suggested that myofibroblasts originated from resident VSMCs ([Figure 1](#F1){ref-type="fig"}).

![Possible role of VSMCs in radiation-induced cardiac fibrosis. Partially reproduced with permission from [@B204].](fcell-08-00140-g001){#F1}

The NLRP3 inflammasome is also involved in regulation of the expression of profibrotic cytokines (e.g., TGF-β, PDGF, and IL-6) ([@B7]). [@B199] showed that NLRP3 inflammasome activation augmented TGF-β signaling in the kidney epithelium. TGF-β1-induced EMT, and induction of MMP-9 and αSMA were significantly impaired in *Nlrp3*-deficient murine renal tubular epithelial cells (TECs). Mitochondrial NLRP3 protein has been shown to directly induce ROS production, resulting in increased TGF-β/Smad signaling and fibrosis without inflammasome formation ([@B16]). The crosstalk between inflammasome-independent NLRP3 and TGFR signaling suggests the essential role of NLRP3 in myofibroblast differentiation and ECM accumulation ([@B7]). A recent study indicated that triptolide (TP) attenuated cardiac fibrosis by interrupting NLRP3-TGFβ1-Smad signaling ([@B141]). Coriolus versicolor (CV) was also shown to alleviate cardiac fibrosis through suppression of the TGF-β/Smad pathway and NLRP inflammasome activation ([@B201]). Similarly, NLRP3 deficiency resulted in reduced TGF-β- and PDGF-BB-induced proliferation of *Nlrp3*-deficient renal fibroblasts ([@B7]). [@B92] showed that hypoxia-reoxygenation-induced ROS production and K^+^ efflux stimulated inflammasome activation in cardiac fibroblasts, but not cardiomyocytes. Radiation has been shown to induce robust production of ROS, which results in differentiation of CD4^+^ T cells into Th2 lymphocytes that secrete potent profibrotic cytokines such as IL-4 and IL-13 ([@B12]; [@B18]). Nucleotide-binding domain and leucine-rich-repeat-containing family pyrin 3 can directly promote Th2 programming without inflammasome formation ([@B20]), NLRP3 can also modulate M2 macrophage polarization via upregulation of IL-4 ([@B120]). Taken together, these findings indicate that NLRP3 inflammasome exhibits a complex function in radiation-induced cardiovascular fibrosis.

Therapeutic Targeting of NLRP3 Against Rihd {#S5}
===========================================

Characterization of the underlying mechanisms of activation of the NLRP3 inflammasome may allow for development of effective inhibitors or regulators as therapeutic agents for RIHD. A number of candidate NLRP3 inhibitors have exhibited promising therapeutic effects against inflammatory disorders. These inhibitors primarily target NLRP3, other inflammasome components, or related signaling events.

Three therapeutics agents against IL-1/IL-1R have been approved by the US FDA for treatment of multiple inflammatory diseases: anakinra (recombinant antagonist against the IL-1 receptor), rilonacept (decoy receptor that binds IL-1β), and as canakinumab (a specific antibody against IL-1β) ([@B35]). Two other inhibitory antibodies, MAPp1 for IL-1α and GSK1070806 for IL-18, are under development ([@B174]). The success of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) demonstrated the clinical translational potential of inhibitors against NLRP3-driven immunopathological diseases. This study evaluated the impact of canakinumab on occurrence and recurrence of CVDs (e.g., MI, stroke). Standard canakinumab administration resulted in a 15% decrease in MI and cardiovascular mortality compared to placebo. The CANTOS trial was the first study to demonstrate the translational significance of the proatherogenic effect of IL-1β, as evidenced by the finding that clinical outcomes of CVD were improved by interfering with IL-1β production or signaling ([@B149]). A recent gene expression analysis of both irradiated and non-irradiated human blood vessels from the Biobank of Radiated Tissues at Karolinska (BiRKa) was conducted, suggesting the involvement of NLRP3-inflammasome and potential treatment using IL-1 inhibitors. According to their findings, treatment with anakinra in irradiated *Apoe*^--/--^ mice significantly alleviated arterial inflammation ([@B28]).

Development of oral small molecules specific for NLRP3 inflammasome inhibition might be a more promising, less invasive, and more cost-effective strategy ([@B220]). Among the inhibitors summarized in [Table 1](#T1){ref-type="table"}, compound MCC950 is the most promising NLRP3 inhibitor candidate because it selectively suppresses NLRP3 inflammasome signaling in human and mouse macrophages. In addition, MCC950 does not affect non-NLRP3 inflammasomes, TLR-mediated priming signals, or IL-1α releasing. MCC950 exhibits striking therapeutic effects against a variety of preclinical immunopathological models such as atherosclerosis, cardiac arrhythmia, MI, and colitis ([@B115]; [@B174]). Another NLRP3 specific inhibitor, 16673-34-0 exerted protective effects against myocardial ischemia-reperfusion injury and acute peritonitis ([@B114]). Pharmacological interventions targeting alternative inflammasome constituents are being actively investigated ([@B220]). Of note, only a small number of inhibitory therapeutics that target NLRP3 or its downstream effectors and pathways show potent efficacy for treatment of NLRP3-associated diseases. Other inhibitors such as AZD9059 and GSK1482169 for P2 × 7, and VX VX-740 and VX-756 for caspase-1 also did not induce therapeutic effects against NLRP3-related diseases due to ineffectiveness or severe hepatic toxicity ([@B140]). Interestingly, non-specific pharmacological interventions can also modulate NLRP3 inflammasome activity. Atorvastatin was found to effectively suppress NLRP3 inflammasome level in CAD ([@B152]). Certain antidiabetic medicines such as biguanides, thiazolidinediones, and inhibitors of dipeptidyl peptidase 4 have the potential to regulate the activation of NLRP3 inflammasome ([@B222]). An antioxidant, melatonin, could also function as an anti-inflammatory agent by inhibiting the activity of NLRP3 inflammasome ([@B52]).

###### 

Inhibitors against NLRP3 inflammasome.

  Target specificity   Inhibitor                   Diseases              Clinical status                                         References    
  -------------------- --------------------------- --------------------- ------------------------------------------------------- ------------- -------------
                       NLRP3                       MCC950                Inflammatory diseases                                   Phase II      [@B31]
                       NLRP3                       Tranilast (MK-341)    Inflammatory diseases                                   Approved      [@B85]
                       NLRP3                       OLT1177               Inflammatory diseases                                   Phase II      [@B124]
                       NLRP3                       CY-09                 Inflammatory diseases                                   Preclinical   [@B88]
                       NLRP3                       JC171                 Inflammatory diseases                                   Preclinical   [@B64]
                       NLRP3                       JC124                 Traumatic neuroinflammatory response                    Preclinical   [@B105]
                       NLRP3                       INF39                 Inflammatory diseases                                   Preclinical   [@B30]
                       NLRP3                       NBCs                  Inflammatory diseases                                   Preclinical   [@B10]
                       NLRP3                       Apigenin              Inflammatory diseases                                   Preclinical   [@B112]
                       NLRP1, NLRP3, NK-κB, IKKβ   Parthenolide          Inflammatory diseases, Cystic fibrosis                  Preclinical   [@B89]
                       NLRP3                       ILG                   Obesity, hypercholesterolemia, and insulin resistance   Preclinical   [@B80]
                       NLRP3                       Fc11a-2               Inflammatory diseases                                   Preclinical   [@B117]
  NLRP3                NLRP3                       BOT-4-one             Inflammatory diseases                                   Preclinical   [@B163]
                       NLRP3                       Glyburide             Inflammatory diseases                                   Preclinical   [@B106]
                       NLRP3                       MNS                   Inflammatory diseases                                   Preclinical   [@B75]
                       NLRP3                       Flufenamic acid       Alzheimer's disease                                     Preclinical   [@B34]
                       NLRP3                       16673-34-0            Acute myocardial infarction                             Preclinical   [@B123]
                       NLRP3                       Oridonin              Inflammatory diseases                                   Preclinical   [@B73]
                       NLRP3                       Kynurenic acid        Stress-related colonic disorder                         Preclinical   [@B231]
                       NLRP3                       Formononetin          Inflammatory diseases                                   Preclinical   [@B209]
                       NLRP3                       Triptolide            Cardioprotective                                        Preclinical   [@B110]
                       NLRP3                       Andrographolide       Inflammatory diseases                                   Preclinical   [@B66]
                       NLRP3                       Celastrol             Inflammatory diseases                                   Preclinical   [@B212]
                       NLRP3                       BHB                   Inflammatory diseases                                   Preclinical   [@B217]
  Caspase-1            Caspase-1                   VX-740                Inflammatory diseases                                   Preclinical   [@B151]
                       Caspase-1                   VX-765                Inflammatory diseases                                   Preclinical   [@B202]
                       IL-1R1                      Anakinra              Cystic fibrosis                                         Approved      [@B86]
                       IL-1β                       Canakinumab           Cardiovascular events                                   Approved      [@B159]
                       IL-1β                       Gevokizumab           Cardiac remodeling and coronary dysfunction             Preclinical   [@B72]
                       IL-1β                       Pralnacasan           Inflammatory diseases                                   Preclinical   [@B151]
  Cytokines            IL-1β                       Curcumin              Inflammatory diseases                                   Preclinical   [@B60]
                       IL-1βR                      Rilonacept            CAPS                                                    Approved      [@B57]
                       IL-1α                       Xilonix               Femoral artery restenosis                               Phase II      [@B39]
                       IL-4/IL-13                  SAR156597             IPF                                                     Phase II      [@B146]
                       TGF-β                       SHP-627               Cardiac fibrosis                                        Preclinical   [@B225]
                       PDGFR                       Imatinib              NSF, IPF                                                Phase II      [@B33]
                       Endothelin-1 receptor       Macitentan            Heart failure                                           Phase II      NCT03153111
                       Angiotensin II              Losartan              Cardiac fibrosis                                        Preclinical   [@B53]
  Related pathways     Relaxin receptor            Serelaxin             Cardiac fibrosis                                        Preclinical   [@B210]
                       IKK                         IMD-1041              Cardiac fibrosis                                        Preclinical   [@B178]
                       IKK                         Bardoxolone methyl    Pulmonary hypertension                                  Phase II      [@B25]
                       NF-κB                       BAY 11-7082           Inflammatory diseases                                   Preclinical   [@B87]
                       NK-κB                       Baicalein             Renal fibrosis                                          Preclinical   [@B227]
                       NF-κB                       Wogonoside            Inflammatory diseases                                   Preclinical   [@B173]
                       JNK                         Tanzisertib (CC930)   IPF                                                     Phase II      NCT01203943
                       TLR-4                       Alpinetin             Inflammatory diseases                                   Preclinical   [@B74]
                       MAPK                        MMI-0100              Cardiac fibrosis                                        Preclinical   [@B127]
                       Peroxiredoxin 1             AI-44                 Inflammatory diseases                                   Preclinical   [@B118]
                       AhR/Nrf2/NQO1               Cardamonin            Inflammatory diseases                                   Preclinical   [@B194]
                       AMPK/ULK1/p62               Ginsenoside Rd        Inflammatory diseases                                   Preclinical   [@B116]
                       Cathepsin B                 VBY-376               Liver fibrosis                                          Preclinical   [@B208]
                       Smad2/4                     Pentoxifylline        Cardiac fibrosis                                        Preclinical   [@B224]
                       NOX4                        GKT-137831            Cardiac fibrosis                                        Preclinical   [@B228]
                       ROS                         *N*-acetylcysteine    Cardiac fibrosis                                        Preclinical   [@B55]
                       ROS                         Levornidazole         Inflammatory diseases                                   Preclinical   [@B200]
                       ROS                         Mitoquinone           Cardiac fibrosis                                        Preclinical   [@B58]
                       ROS                         LGM2605               Radiation damage                                        Preclinical   [@B22]

Conclusion and Perspectives {#S6}
===========================

Radiation-induced cardiovascular injury has received increased attention due to the growing population of cancer survivors exposed to chest radiation. Although great improvements have been made in radiotherapy techniques, asymptomatic patients are at increased risk for development of RIHD. Exposure to low-dose irradiation may result in adverse cardiovascular effects. Studies have shown that acute and chronic inflammatory responses are essential in development of RIHD. Increasing evidence has indicated that the NLRP3 inflammasome is involved in radiation damage. In addition, multiple cellular effects of radiation, such as ROS production and generation of DAMPs resulting from cell death, can further strengthen NLRP3 inflammasome activation ([Figure 2](#F2){ref-type="fig"}). However, the mechanisms by which the NLRP3 inflammasome functions in RIHD requires further characterization. In addition, previous studies showed that two evolutionarily conserved degradation pathways, ubiquitin-proteasome and autophagy, negatively regulate NLRP3 inflammasome activation ([@B166]; [@B232]). Small molecule has been developed to inhibit NLRP3 inflammasome activity by interplaying between ubiquitination and autophagy ([@B69]). MicroRNA was also identified to respond to chronic inflammation in RIHD ([@B38]). Future translational researches are needed to determine whether NLRP3 inflammasome inhibition and whether these pharmacological candidate inhibitors mentioned above are promising to prevent radiation-induced cardiovascular injury, inflammation, and late fibrosis. Additionally, it seems to be rational to start with an early and short-term IL-1β blockage treatment directly after radiotherapy exposure. It is based on the concept that the intervention might not work effectively in already established RIHD, where the chronic inflammatory response is advanced ([@B28]). Further studies are required to evaluate the optimal timing and treatment-duration of NLRP3 inflammasome signaling inhibition to prevent RIHD. Experimental animal models for RIHD are also needed to be optimized to accelerate the investigation of the underlying mechanism and development of novel treatment strategies.

![Multiple effects of radiation on NLRP3 inflammasome activation. Radiation-induced NF-κB activation is responsible for the upregulation of NLRP3 and pro-interleukin-1β. Second signals come from multiple pathways: water radiolysis, K^+^ efflux, endoplasmic reticulum (ER) stress, mitochondrial dysfunction, ceramide pathway, and lysosomal rupture pathways, most of which appear to converge in the production of reactive oxygen species (ROS). The primary and secondary signals triggers the NLRP3 inflammasome activation, resulting in the maturation of caspase 1 and IL-1β. Two evolutionarily conserved degradation pathways, ubiquitin-proteasome and autophagy, negatively regulate NLRP3 activation.](fcell-08-00140-g002){#F2}
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